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and the overall, crude incidence density for this pneumoco-
niosis during the 12-year study period was 2.7 (95% confi-
dence interval 2.5–2.9) per 100,000 person-years. The inci-
dence increased progressively during the period 1997–2005 
and then decreased slightly during the period 2006–2008, 
even after controlling for the strong effect of an ageing UK 
population. The non-asbestos-related pneumoconioses, in 
contrast to asbestosis, showed a progressive reduction in in-
cidence from 2003 onwards.  Conclusions: This study dem-
onstrates that the pneumoconioses remain an important 
public health issue and, furthermore, documents an overall 
increase in asbestosis incidence in the UK between 1997 and 
2008.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The pneumoconioses are a group of interstitial lung 
diseases caused by inhalation and retention of inorganic 
dusts. These diseases generally evolve over decades of oc-
cupational exposure to mineral dusts and are character-
ized by the formation of nodular, fibrotic changes to the 
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 Abstract 
 Background: The incidence of the pneumoconioses in the 
UK is primarily estimated using occupational-based regis-
tries and disability pension schemes. These sources indicate 
a downward trend in the incidence of the pneumoconioses 
from 1995 onwards. There are no previously published gen-
eral population-based observational studies quantifying the 
incidence of the pneumoconioses in the UK.  Objectives: The 
aim of this study was to investigate the incidence of the 
pneumoconioses in the UK general population between 
1997 and 2008 using data from the General Practice Re-
search Database (GPRD).  Methods: Data from the UK-based 
GPRD were used to estimate the incidence of pneumoconio-
ses over a 12-year period (1997–2008). Crude incidence rates 
for asbestosis and non-asbestos-related pneumoconioses 
were stratified by gender, age group and calendar period, 
and rate ratios were adjusted using Poisson regression.  Re-
sults: The majority of cases was diagnosed with asbestosis, 
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lung parenchyma  [1] . In the absence of extremely high ex-
posure to such particles, there is a relatively long time lag 
between first-time occupational exposure and clinically 
detectable disease. This is reflected in the fact that the ma-
jority of incident cases is detected in retired workers  [2] .
 The primary data sources used to investigate the inci-
dence and prevalence of the pneumoconioses in the UK 
are the Department for Work and Pensions Industrial In-
juries and Disablement Benefit scheme and The Health 
and Occupation Reporting (THOR) network. During the 
period 1998–2008, the number of new cases of pneumo-
coniosis reported by chest and occupational physicians 
within the THOR network fluctuated between 108 and 
321 cases per year  [3] . Trends in incidence of the pneumo-
conioses from both sources are difficult to interpret due 
to varying definitions of disease states and changing eli-
gibility criteria for compensation benefits over time. Ad-
ditionally, it is known that case numbers have been af-
fected by fluctuations in the numbers and reporting hab-
its of participating health care practitioners over time  [3] . 
Data from THOR and the Industrial Injuries and Dis-
ablement Benefit scheme suggest a downward trend in 
the annual number of new pneumoconiosis cases from 
2005 onward  [3, 4] . However, as is the case when using 
data from disease registries, measures of disease frequen-
cy from both of these sources may be underestimated due 
to case ascertainment and selection biases.
 The UK General Practice Research Database (GPRD) 
contains anonymized electronic patient records collected 
from routine general practice. The geographic, age and 
gender distributions of the GPRD population have been 
shown to be representative of the UK general population 
 [5] . The aim of this study was to investigate the incidence 
of the pneumoconioses in the UK general population be-
tween 1997 and 2008 using data from the GPRD.
 Materials and Methods 
 Data Source 
 The GPRD has been described elsewhere in detail  [5] , but 
briefly, it is a large and well-validated UK-based database that was 
established in June 1987. The GPRD encompasses nearly 5 million 
patients who are or were enrolled with selected general practitio-
ners throughout the UK, covering approximately 50 million pa-
tient-years of follow-up. The participating general practitioners 
have been trained to record medical information in a standard 
manner and to provide anonymized records to the GPRD Group 
within the Medicines and Healthcare products Regulatory Agen-
cy (MHRA), the UK’s medicines and devices regulator. The re-
corded data include demographic information, medical diagno-
ses and drug prescriptions. The Boston Collaborative Drug Sur-
veillance Program and its associated researchers at the Basel 
Pharmacoepidemiology Unit (University of Basel) use a large sub-
set of data from the GPRD; data from general practices that have 
failed to report consistent numbers of drug prescriptions and di-
agnostic codes over time have been removed from the Boston Col-
laborative Drug Surveillance Program GPRD  [6] . Data from the 
GPRD have been used in previous studies involving interstitial 
lung disease, and use of the data for respiratory epidemiology has 
been validated  [7, 8] . The GPRD is managed by the MHRA, and 
the present study protocol was approved by the Independent Sci-
entific Advisory Committee for MHRA database research.
 Study Population 
 We identified in the GPRD all patients with a first-time diag-
nosis of a pneumoconiosis between 1 January 1997 and 31 Decem-
ber 2008. Diagnoses in the GPRD are coded using the Read cod-
ing system, and our list of pneumoconiosis diagnoses included 
any Read code explicitly mentioning pneumoconiosis, silicosis, 
silica/silicate pneumoconiosis, silicotic fibrosis, talc pneumoco-
niosis, siderosis, berylliosis, stannosis, asbestosis and coal work-
er’s pneumoconiosis. Read codes without explicit mention of a 
pneumoconiosis, such as ‘Pneumopathy due to inhalation of oth-
er dust NOS’, were not used. In order to increase the likelihood of 
capturing incident rather than prevalent cases, we excluded pa-
tients with less than 3 years of active recording history prior to the 
date of the first pneumoconiosis diagnosis.
 Data Analysis 
 Person-time denominators for the calculations of incidence 
density were derived from the GPRD. For each calendar period, 
only those patients in the GPRD who were alive, actively regis-
tered and had at least 3 years of recorded history contributed per-
son-time to the denominators. Incident cases were grouped into 
four age groups ( ! 60, 60–69, 70–79 and  6 80 years), and calendar 
time was divided into four 3-year periods (1997–1999, 2000–2002, 
2003–2005 and 2006–2008). Crude incidence rates were calcu-
lated for asbestos-related pneumoconiosis (i.e. asbestosis) and for 
non-asbestos-related pneumoconioses separately. The crude rates 
were stratified by gender, age group and calendar period, with 
exact 95% confidence intervals (CIs) being calculated from the 
Poisson distribution. In order to model disease incidence and es-
timate incidence rate ratios, fixed-effects Poisson multivariate re-
gression was used. We accounted for overdispersion in all regres-
sion models using the quasi-likelihood approach, that is, by fixing 
the scaled deviance at unity and introducing a dispersion param-
eter into the model which adjusted the standard errors of the pa-
rameter estimates. All analyses were performed with the statisti-
cal software SAS (release 9.2, SAS Institute, Inc., Cary, N.C., USA).
 Results 
 A total of 1,070 patients with an incident diagnosis of 
any type of pneumoconiosis were identified during the 
period 1997–2008, which included 840 cases of asbestosis 
(87.5%) and 230 cases of non-asbestos-related pneumoco-
nioses. The frequency distribution of incident diagnoses 
is shown in  table 1 .
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 Non-Asbestos-Related Pneumoconiosis 
 The mean age (SD) at diagnosis was 70 years (13.9), and 
217 cases (94%) were male. Females were younger than 
males at the time of first diagnosis [57.8 years (21.8) vs. 
71.1 years (13.0), respectively], and the majority of diag-
nosed cases was 70 years of age and over.
 Between 1997 and 2008, the overall incidence density 
rate of the non-asbestos-related pneumonconioses was 
0.74 (95% CI 0.65–0.84) per 100,000 person-years, and 
the rate in males was approximately 16 times the rate in 
females. The incidence density increased during the pe-
riod 1997–2002 [from 0.82 (95% CI 0.62–1.07) during 
1997–1999 to 1.09 (95% CI 0.87–1.35) during 2000–2002 
per 100,000 person-years] and decreased progressively 
thereafter from 2003 to 2008. Crude incidence rates by 
calendar period for the non-asbestos-related pneumo-
conioses are shown in  table 2 . Poisson regression model-
ling of incidence rates for the non-asbestos-related 
pneumoconioses yielded no statistically significant het-
erogeneity of rates over time (p for trend = 0.1017;  ta-
ble 3 ).
 Asbestosis 
 The mean age (SD) at diagnosis was 69 years (11.4), and 
784 cases (93%) were male. Females were younger than 
Table 1. F requency of incident pneumoconiosis diagnoses (n = 
1,070)
Diagnosis code Fre-
quency
Percentage
Asbestos-related (total) 840 100.00%
Asbestosis 826 98.33%
Asbestosis NOS 14 1.67%
Non-asbestos-related (total) 230 100.00%
Pneumoconioses NOS 173 75.22%
Coal worker’s pneumoconiosis 17 7.39%
Silica and silicate pneumoconiosis 7 3.04%
Talc pneumoconiosis 1 0.43%
Simple silicosis 5 2.17%
Massive silicotic fibrosis 1 0.43%
Silica pneumoconiosis NOS 6 2.61%
Pneumoconiosis due to other inorganic dust 1 0.43%
Chronic beryllium disease 1 0.43%
Siderosis 8 3.48%
Stannosis 1 0.43%
Pneumoconiosis due to inorganic dust NOS 9 3.91%
 NOS = Not otherwise specified. 
Table 2. C rude incidence rates for non-asbestos-related pneumo-
coniosis diagnoses (n = 230)
Cases
n
Total 
person-years
IR 95% CI 
(exact Poisson)
Overall 230 31,165,672.41 0.74 0.65–0.84
Gender
Female 13 16,421,082 0.08 0.42–1.35
Male 217 14,744,590 1.47 1.28–1.68
Age group
<60 years 39 23,309,579.76 0.17 0.12–0.23
60–69 years 50 3,474,347.44 1.44 1.07–1.90
70–79 years 78 2,689,162.52 2.90 2.29–3.62
>80 years 63 1,692,582.69 3.72 2.86–4.76
Calendar period
1997–1999 55 6,696,773.29 0.82 0.62–1.07
2000–2002 83 7,646,978.15 1.09 0.87–1.35
2003–2005 57 8,232,635.23 0.69 0.52–0.90
2006–2008 35 8,589,285.74 0.41 0.28–0.57
I R = Incidence rate (density) per 100,000 person-years.
Table 3. P oisson regression modelling of incidence for the non-
asbestos-related pneumoconioses (n = 230)
IRR 95% CI LRT 
p value
Gender <0.0001
Female (ref.) 1.00 –
Male 16.15 7.26–35.96
Age group 0.21971
<60 years (ref.) 1.00 –
60–69 years 1.43 0.79–2.61
70–79 years 2.29 1.32–3.97
>80 years 2.12 1.20–3.76
Calendar period 0.10171
1997–1999 (ref.) 1.00 –
2000–2002 1.30 0.80–2.12
2003–2005 0.82 0.48–1.39
2006–2008 0.49 0.27–0.90
I RR = Incidence rate ratio; LRT = likelihood ratio test.
1 p for trend.
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males at the time of first diagnosis [61.8 years (22.1) vs. 
70.0 years (10.0), respectively], and the majority of cases 
were diagnosed in the age group 60–79 years.
 Between 1997 and 2008, the overall incidence density 
rate of asbestosis was 2.7 (95% CI 2.5–2.9) per 100,000 
person-years, and the rate in males was approximately 
18 times the rate in females. The analysis of crude inci-
dence density for asbestosis yielded progressively in-
creasing rates during the period 1997–2005 [from 1.6 
(95% CI 1.4–2.0) during the period 1997–1999 to 3.2 
(95% CI 2.9–3.6) per 100,000 person-years], with a slight 
downward blip during the period 2006–2008. Crude in-
cidence rates by calendar period for asbestosis are shown 
in  table 4 .
 In the asbestosis cohort, there was evidence of statisti-
cally significant heterogeneity of incidence rate ratios 
over time (p = 0.024), after adjusting for the effects of age 
and gender. The incidence density increased from the pe-
riod 1997–1999 to 2000–2002 by a factor of 1.5. Using the 
same baseline period, the incidence nearly doubled dur-
ing the period 2003–2005 (incidence rate ratio 1.9). Inci-
dence rate ratios for asbestosis are shown in  table 5 .
 To provide an additional estimate of the average an-
nual increase in the incidence of asbestosis, we repeated 
our analyses fitting year as a continuous variable. After 
controlling for the effects of age and gender, we estimated 
the average annual increase in the incidence of asbestosis 
to be 6% during the 12-year study period (incidence rate 
ratio 1.064, 95% CI 1.04–1.09; p  ! 0.0001).
 Discussion 
 In this large, general population-based cohort of pneu-
moconiosis patients, the overall incidence rate for asbes-
tos-related and non-asbestos-related pneumoconioses 
was approximately 3 and 1 per 100,000 UK population 
per year, respectively, suggesting that each year during 
the period 1997–2008 there were approximately 1,800 
new cases of asbestosis and 600 new cases of non-asbes-
tos-related pneumoconiosis in the UK. The incidence of 
asbestosis increased progressively during the period 
1997–2005 and then decreased slightly during the period 
2006–2008, while the incidence of non-asbestos-related 
pneumoconiosis showed progressive decline from 2003 
to 2008. Incidence rates were substantially higher in men 
than in women, likely reflecting the industrial-occupa-
tional nature of the disease etiology.
 The majority of cases in our cohort (approx. 80%) was 
diagnosed with asbestosis, and the observed increase in 
incidence during the study period would seem to be in 
line with the estimation that the peak global incidence 
Table 4. C rude incidence rates for asbestosis (n = 840)
Cases
n
Total 
person-years
IR 95% CI 
(exact Poisson)
Overall 840 31,165,672.41 2.70 2.52–2.88
Gender
Female 56 16,421,082 0.34 0.26–0.44
Male 784 14,744,590 5.32 4.95–5.70
Age group
<60 years 108 23,309,579.76 0.46 0.38–0.56
60–69 years 280 3,474,347.44 8.06 7.14–9.06
70–79 years 321 2,689,162.52 11.94 10.67–13.32
>80 years 131 1,692,582.69 7.74 6.47–9.18
Calendar period
1997–1999 110 6,696,773.29 1.64 1.35–1.98
2000–2002 195 7,646,978.15 2.55 2.20–2.93
2003–2005 266 8,232,635.23 3.23 2.85–3.64
2006–2008 269 8,589,285.74 3.13 2.77–3.53
I R = Incidence rate (density) per 100,000 person-years.
Table 5. P oisson regression modelling of incidence for asbestosis 
(n = 840)
IRR 95% CI LRT 
p value
Gender <0.0001
Female (ref.) 1.00 –
Male 17.87 11.36–28.09
Age groups <0.00011
<60 years (ref.) 1.00 –
60–69 years 17.56 12.13–25.42
70–79 years 28.14 19.57–40.48
>80 years 22.58 14.77–34.55
Calendar period 0.02381
1997–1999 (ref.) 1.00 –
2000–2002 1.54 1.04–2.27
2003–2005 1.91 1.32–2.76
2006–2008 1.76 1.22–2.55
I RR = Incidence rate ratio; LRT = likelihood ratio test. 
1 p for trend.
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of asbestos-related disease is expected to occur 30–40 
years after the period of peak asbestos usage (i.e. the 
1960s and 1970s)  [9] . This is further reflected in a report 
by the UK Health and Safety Executive which predicts 
increasing rates of mesothelioma-related mortality until 
around 2015, after which rates are expected to decline 
 [10, 11] . Therefore, the projected, overall annual esti-
mate of approximately 1,800 new cases of asbestosis will 
probably not continue far into the future. From the anal-
ysis of non-asbestos-related pneumoconiosis, it can be 
seen that the incidence of pneumoconiosis due to causes 
other than asbestos has declined over time, except for a 
relative rise in incidence noted during the period 2000–
2002.
 A potential weakness of the present study could be the 
validity of pneumoconiosis diagnoses, as we have not 
tested these directly. However, the validity of many dis-
ease diagnoses has been assessed in the UK GPRD and 
consistently found to be high  [6, 12, 13] . Furthermore, 
other researchers have reported a high validity of the di-
agnosis of idiopathic pulmonary fibrosis, another inter-
stitial lung disease, in the GPRD  [14] . Moreover, it is un-
likely that general practitioners would record a pneumo-
coniosis diagnosis without confirmation by specialist 
referral. Therefore, we expect the diagnoses used for the 
present study to have high specificity.
 On the other hand, the authors are aware that the 
sensitivity of the diagnoses used may not be as high as 
the specificity. Two main reasons for this are the poten-
tial for misclassification of true pneumoconiosis cases 
into less specific disease diagnosis categories and the 
possibility of having missed less severe cases. For in-
stance, we did not use less specific respiratory-related 
diagnosis codes such as ‘lung disease due to other exter-
nal agents NOS’ or ‘other external agent causing respira-
tory condition’ in our case selection algorithm. Overall, 
there were 649 cases with such an unspecific diagnosis 
which we subsequently reviewed in more detail. Only 10 
of them (1.5%) had some evidence of a pneumoconiosis 
diagnosis at a later point in time in their patient record, 
which makes substantial misclassification unlikely. It is 
also possible that under-diagnosis on the part of gen-
eral practitioners (and hence non-referral to specialists) 
is present in this study or that less severe cases have sim-
ply escaped detection by general practitioners and/or 
specialists. Unfortunately, the degree to which both pos-
sibilities might have occurred cannot be readily quanti-
fied in retrospective, observational database research. 
Thus, it is possible that we did not have available for 
analysis all true pneumoconiosis cases from the given 
sampling frame, which means that we may have under-
estimated the true incidence density of the pneumoco-
nioses in the UK. Furthermore, we cannot be certain 
that all newly identified cases were indeed incident cas-
es. However, we excluded cases with less than 3 years of 
recorded medical history in order to minimize the pos-
sibility of including prevalent cases in our incidence nu-
merators, so we expect the occurrence of such error to 
be minimal. To the extent that this error occurred, it will 
have resulted in a small overestimation of the incidence 
density rates. Moreover, the percentage of cases disre-
garded due to the above exclusion criterion was 11% of 
the total number of cases identified during the defined 
study window (2,071 vs. 1,843), and the percentages of 
cases excluded across the study time periods remained 
relatively stable at 10–12%. This would support the con-
clusion that the results presented here are not influ-
enced by fluctuations in the frequency of recorded diag-
noses of pneumoconiosis.
 Despite the potential limitations mentioned above, 
this study determined the best current estimates of inci-
dence density for inorganic dust pneumoconioses in the 
UK general population. We have been unable to find any 
other general population-based cohort analyses in the 
UK with which to compare our results. Also, comparison 
of our incidence estimates to those published from the 
Surveillance of Work-Related and Occupational Respira-
tory Disease – as part of the THOR network – is difficult. 
Recent analyses of Surveillance of Work-Related and Oc-
cupational Respiratory Disease data yielded an average 
annual decline in pneumoconiosis incidence of –0.8% 
(95% CI –4.8 to +3.3) over the period 1999–2006  [15] . 
However, with respect to age and gender demography, 
some similarities can be noted; nearly all cases were 
males ( 1 97%) with a mean age between 66 and 70 years, 
and approximately 55% of all cases were observed in the 
60–75 years age range. Nevertheless, we acknowledge 
that employed adults generally seek medical care less of-
ten than the unemployed, which may partially explain 
the relatively higher frequency of first-time pneumoco-
niosis diagnosis during retirement age. Finally, it is ac-
knowledged by the Health Safety Executive – the nation-
al independent watchdog for work-related health, safety 
and illness in Great Britain – that incidence figures may 
be substantially underestimated by THOR ‘since the 
scheme will only include those cases that are serious 
enough to be seen by a chest consultant, or that occur in 
individuals with access to occupational physicians’  [3] . 
By the same token, we acknowledge the potential for un-
der- or overrecognition of the pneumoconioses in our 
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study, should the catchment area of contributing prac-
tices not be representative of the industrial mix in the 
UK. However, we expect the potential for such bias to be 
minimal, since the geographical distribution of the par-
ticipating practices in the GPRD is representative of the 
UK population  [5] .
 The observed upward trend in asbestosis incidence in 
the present study should be interpreted with caution. We 
cannot tell whether this finding reflects a real increase 
or whether it is, at least to a certain extent, attributable 
to secular trends. Firstly, during the study window, ma-
jor political changes in the NHS occurred, including 
more than a doubling in funding under the auspices of 
the New Deal  [16] . This investment in national health 
care was in part used to boost the capacity of NHS ser-
vices and to modernize facilities, thus potentially in-
creasing the likelihood of detecting new cases of pneu-
moconioses. Secondly, a certain proportion of incident 
cases in this time period may have been due to increased 
recognition of interstitial lung diseases in general via the 
increased use of high-resolution computed tomography. 
Thirdly, following publication of both the British Tho-
racic Society’s guideline on diagnosis and care of diffuse 
parenchymal lung disease in 1999  [17] and the American 
Thoracic Society/European Respiratory Society consen-
sus statements on idiopathic interstitial pneumonia in 
2002  [18] , a greater appreciation of the value of precise 
diagnosis according to defined criteria will likely have 
occurred, not to mention increased patient expectations. 
Finally, the observed increase in non-asbestos-related 
pneumoconiosis from 1997–1999 to 2000–2002 could be 
partly attributable to a publicity campaign by the De-
partment for Work and Pensions around 2002 inviting 
people whose claims had been wrongly disallowed be-
tween 1994 and 1999 to re-claim  [3] . For the above rea-
sons, an increase in case ascertainment may have played 
a role in the observed increase in the incidence density 
of asbestosis. However, the observed numerical decline 
in the incidence of the non-asbestos-related pneumoco-
nioses from 2003 onwards would argue against increased 
case ascertainment being responsible for the progressive 
upward trend in the incidence of asbestosis until the end 
of 2005.
 Conclusions 
 This study makes use of data from a well-validated da-
tabase which has consistently been found to be represen-
tative of the UK general population. To our knowledge, 
this is the first general population-based observational 
study quantifying incidence rates of pneumoconioses in 
the UK. Further research using data sources such as the 
UK GPRD is needed to assess future trends in pneumo-
coniosis incidence and to confirm the assumption that 
asbestos-related diseases are truly beginning to decline in 
incidence as a consequence of health and safety measures 
enacted at the end of the last century.
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